UDG Healthcare has reported pre-tax profits of €91.6m for the full year to the end of September, a 10% increase on the previous year.
Revenue at the international healthcare services provider rose by 3% higher to €943m.
The company is proposing a 5% increase in final dividend per share, giving it a full year yield of 11.5 cent.
During the year, UDG completed the sale of its United Drug Supply Chain business and MASTA which resulted in a net profit of 132.1m.
It also completed the purchase of Pegasus in August and STEM after the end of the year. It noted that both of these deals are an "excellent strategic fit" for its Ashfield business.
"2016 saw the continuing business deliver another year of good growth as the group positioned itself for the next phase of development, following the disposal of the United Drug Supply Chain businesses," commented its chief executive Brendan McAtamney.
"The group has made significant progress in delivering on its strategy to capitalise on an increasing trend among healthcare companies to outsource non-core and specialist activities on an international basis," the CEO added.
He said the company remains focused on delivering organic growth and executing strategic acquisition opportunities, complementary to its existing high growth businesses.
UDG Healthcare said that gross revenues in its Ashfield operations for the year rose by an underlying 8% to €585.5m while operating profits increased by 9% to €63.6m.
Revenues at its Sharp business rose by 7% to €266.4m while operating profits also increased by 12% to €34.4m.
It noted that while Sharp US delivered strong growth with revenues up 15% and operating profits rising by 19%, Sharp Europe saw an operating loss of €1.2m.
It said that despite the volume of activity across its European facilities remaining below requirements, the improved business development pipeline in the second half of the year leaves the business well positioned.
UDG Healthcare also said that revenues at its Aquilant eased by 1% to €92.2m on an underlying position, while operating profits slipped 2% to €6.2m.
